National Health Investors price target raised to $88 from $80 at KeyBanc

KeyBanc raised the firm’s price target on National Health Investors (NHI) to $88 from $80 and keeps an Overweight rating on the shares. The firm views National Health Investors as an attractive way to gain exposure to a Healthcare REIT with an attractive cost of capital and below average leverage that can capitalize on the current investment landscape and drive upside to 2026 and 2027 NFFO estimates. Importantly, the investments should continue to grow the company’s Senior Housing Operating Portfolio exposure and potentially enhance its internal growth profile, over time. Moreover, potential positive catalysts from available market rent resets and lease expirations in early-to-mid 2026 could drive additional upside to NFFO estimates, KeyBanc adds.